Inclisiran vs Laroprovstat

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline

Inclisiran · Leqvio

Marketed by Novartis and partners

Phase 3 in Atherosclerotic Cardiovascular DiseaseRNAi (siRNA)
Partial signal

NCT03397121 · Phase 3 · completed

The trial randomly assigned 482 participants to double-blind inclisiran or placebo, with 242 receiving inclisiran and 240 receiving placebo. Both primary LDL-C comparisons were statistically significant in favor of inclisiran, but LDL-C is a surrogate laboratory endpoint rather than a hard clinical outcome, supporting a moderate evidence grade.

Next expected readout: November 2026 · NCT06501443 (registry estimate)

Reported efficacy

Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -27.14% (95% CI -32.04 to -22.24) vs Part 1 - Placebo 1.4% (95% CI -3.97 to 6.78) (met)

Result source: NCT04652726

Laroprovstat

Developed by AstraZeneca

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall molecule
Reliable signal

NCT06173570 · Phase 2 · completed

The study randomized 428 participants to four AZD0780 dose groups or matched placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the regulator-accepted lipid measure LDL cholesterol, and all four AZD0780-versus-placebo comparisons were statistically significant in the favorable direction (p<0.001).

Next expected readout: January 2027 · NCT07000136 (registry estimate)

Reported efficacy

Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo) (met)

Result source: NCT06173570

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInclisiranLaroprovstat
LDL-C, % change-49.3% vs 4.2%−53.5 vs placebowk 72.9 · n 810NCT03400800
76 other results
  • -56.3% vs 1.3% wk 72.9 · n 781 · Phase 3 · primary NCT03399370
  • -45.8% vs 3.4% n 810 · Phase 3 · primary NCT03400800
  • -51.3% vs 2.5% n 781 · Phase 3 · primary NCT03399370
  • -41.1% vs 8.4% wk 73 · n 242 · Phase 3 · primary NCT03397121
  • -27.1% vs 1.4% wk 47.14 · n 93 · Phase 3 · primary NCT04652726
  • -45.9% vs 1.6% wk 21.43 · n 103 · Phase 3 · primary NCT05888103
  • -38.1% vs 6.2% n 242 · Phase 3 · primary NCT03397121
  • 0.7% vs 2.4% wk 21.43 · n 37 · Phase 3 · primary NCT03851705
  • -21.6% vs 11.7% wk 47.14 · n 9 · Phase 3 · primary NCT04659863
  • -45.6% vs 1.4% wk 47 · n 171 · Phase 3 · primary NCT04873934
  • -60% vs -7% wk 47 · n 205 · Phase 3 · primary NCT04929249
  • -26.1% vs 1.5% wk 51.43 · n 93 · Phase 3 · secondary NCT04652726
  • -26.0% vs 3.3% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -27.8% vs 1.5% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -19% vs 2.1% wk 38.57 · n 93 · Phase 3 · secondary NCT04652726
  • -7.2% vs -1.5% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -32.5% vs 6.4% wk 21.43 · n 93 · Phase 3 · secondary NCT04652726
  • 1.8% vs -2.9% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -23.9% vs -0.1% wk 12.86 · n 93 · Phase 3 · secondary NCT04652726
  • -8.7% vs 3.3% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -19.3% vs 5.4% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -21.6% vs 11.7% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -17.3% vs 10.2% wk 38.57 · n 9 · Phase 3 · secondary NCT04659863
  • -24.1% vs 17% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -26.1% vs 6.8% wk 12.86 · n 9 · Phase 3 · secondary NCT04659863
  • -44.3% vs 2.4% n 194 · Phase 3 · secondary NCT04873934
  • -57.2% vs -2.8% n 222 · Phase 3 · secondary NCT04929249
  • -56.3% vs 9% 300 mg · wk 25.714 · n 96 · Phase 2 · primary NCT04666298
  • -38.4% vs 2.1% 300 mg single dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -52.6% vs 2.1% 300 mg double dose · wk 25.71 · n 59 · Phase 2 · primary NCT02597127
  • -41.9% vs 2.1% 500 mg single dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -51.9% vs 9% 200 mg · wk 25.714 · n 101 · Phase 2 · primary NCT04666298
  • -27.9% vs 2.1% 200 mg single dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -44.9% vs 2.1% 200 mg double dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -47.6% vs 9% 100 mg · wk 25.714 · n 55 · Phase 2 · primary NCT04666298
  • -35.5% vs 2.1% 100 mg double dose · wk 25.71 · n 59 · Phase 2 · primary NCT02597127
  • -59.5% vs -24.3% wk 51.4 · n 898 · Phase 4 · secondary NCT05192941
  • -35.4% vs 1.4% 300 mg single dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -50.5% vs 1.4% 300 mg double dose · wk 30 · n 59 · Phase 2 · secondary NCT02597127
  • -66.2% vs 4.3% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -67.2% vs 2.3% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -43.3% vs -0.9% 300 mg single dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -54.7% vs -0.9% 300 mg double dose · wk 17.14 · n 59 · Phase 2 · secondary NCT02597127
  • -65.7% vs 1.2% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -61.5% vs 2.7% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -62.4% vs 0.2% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -50.9% vs -4.3% 300 mg single dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -51.0% vs -4.3% 300 mg double dose · wk 8.57 · n 59 · Phase 2 · secondary NCT02597127
  • -62.8% vs 1.3% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -47.6% vs 1.7% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -39.2% vs 1.4% 500 mg single dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -46.4% vs -0.9% 500 mg single dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -49.6% vs -4.3% 500 mg single dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -29.0% vs 1.4% 200 mg single dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -42.6% vs 1.4% 200 mg double dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -60.5% vs 4.3% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -62.0% vs 2.3% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -36.9% vs -0.9% 200 mg single dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -49.5% vs -0.9% 200 mg double dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -60.3% vs 1.2% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -53.9% vs 2.7% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -55.6% vs 0.2% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -44.3% vs -4.3% 200 mg single dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -44.3% vs -4.3% 200 mg double dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -55.5% vs 1.3% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -42.1% vs 1.7% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -31.7% vs 1.4% 100 mg double dose · wk 30 · n 59 · Phase 2 · secondary NCT02597127
  • -55.5% vs 4.3% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -54.9% vs 2.3% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -41.4% vs -0.9% 100 mg double dose · wk 17.14 · n 59 · Phase 2 · secondary NCT02597127
  • -53% vs 1.2% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -46.4% vs 2.7% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -50.1% vs 0.2% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -35.7% vs -4.3% 100 mg double dose · wk 8.57 · n 59 · Phase 2 · secondary NCT02597127
  • -52.2% vs 1.3% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -37.1% vs 1.7% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298
-46.6% vs 4.1%−50.7 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -41.1% vs 4.1% 10 mg · wk 12 · n 84 · Phase 2 · primary NCT06173570
  • -33.8% vs 4.1% 3 mg · wk 12 · n 85 · Phase 2 · primary NCT06173570
  • -31.2% vs 4.1% 1 mg · wk 12 · n 86 · Phase 2 · primary NCT06173570
  • -46.4% vs 3.4% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -40.5% vs 3.4% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -33.4% vs 3.4% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -30.5% vs 3.4% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
Non-HDL-C, % change-41.2% vs 2.1%−43.3 vs placebowk 72.9 · n 810NCT03400800
38 other results
  • -47.4% vs -0.1% wk 72.9 · n 781 · Phase 3 · secondary NCT03399370
  • -34.9% vs 7.4% wk 73 · n 242 · Phase 3 · secondary NCT03397121
  • -24% vs 1.2% wk 51.43 · n 92 · Phase 3 · secondary NCT04652726
  • -25.0% vs 1.8% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -25.7% vs 1.8% wk 47.14 · n 92 · Phase 3 · secondary NCT04652726
  • -6.2% vs -1.1% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -29% vs 5.1% wk 21.43 · n 92 · Phase 3 · secondary NCT04652726
  • -40.7% vs -0.1% wk 21.43 · n 103 · Phase 3 · secondary NCT05888103
  • 1.3% vs -1.7% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • 0.4% vs 2.5% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -7.2% vs 2.9% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -20.1% vs 7.1% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -23.3% vs 9.4% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -24% vs 19% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -54.0% vs 1.3% 300 mg · wk 25.71 · n 98 · Phase 2 · secondary NCT04666298
  • -56.8% vs 2.0% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -58.7% vs 0.8% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -57.7% vs 2.0% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -53.2% vs 1.8% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -54.1% vs 0.6% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -54.2% vs 1.0% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -41.2% vs 1.1% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -50.1% vs 1.3% 200 mg · wk 25.71 · n 101 · Phase 2 · secondary NCT04666298
  • -52.9% vs 2.0% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -53.5% vs 0.8% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -52.0% vs 2.0% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -47.2% vs 1.8% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -48.2% vs 0.6% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -48.0% vs 1.0% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -35.7% vs 1.1% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -44.8% vs 1.3% 100 mg · wk 25.71 · n 55 · Phase 2 · secondary NCT04666298
  • -47.9% vs 2.0% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -48.2% vs 0.8% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -46.1% vs 2.0% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -39.8% vs 1.8% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -43.4% vs 0.6% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -44.7% vs 1.0% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -31.4% vs 1.1% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298
-41.6% vs 3.5%−45.2 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -41.4% vs 2.9% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -35.1% vs 3.5% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -34.8% vs 2.9% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -29.9% vs 3.5% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -29.4% vs 2.9% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -26.9% vs 3.5% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
  • -26.1% vs 2.9% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
ApoB, % change-38.1% vs 0.8%−38.9 vs placebowk 72.9 · n 810NCT03400800
38 other results
  • -44.8% vs -1.7% wk 72.9 · n 781 · Phase 3 · secondary NCT03399370
  • -33.1% vs 2.9% wk 73 · n 242 · Phase 3 · secondary NCT03397121
  • -19.3% vs 1.7% wk 51.43 · n 92 · Phase 3 · secondary NCT04652726
  • -21.5% vs 4.2% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -21.9% vs 3.9% wk 47.14 · n 92 · Phase 3 · secondary NCT04652726
  • -5.8% vs 4.5% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -25.1% vs 2.2% wk 21.43 · n 92 · Phase 3 · secondary NCT04652726
  • -36.6% vs 0.2% wk 21.43 · n 103 · Phase 3 · secondary NCT05888103
  • -0.7% vs 2.8% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -0.8% vs 3.5% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -6.4% vs 6.3% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -14.8% vs 10.6% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -18.5% vs 4.5% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -20.3% vs 10% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -46.8% vs 3.8% 300 mg · wk 25.71 · n 98 · Phase 2 · secondary NCT04666298
  • -50.4% vs 3.9% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -51.9% vs 2.0% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -51.9% vs 3.0% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -46.8% vs 2.8% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -48.5% vs 1.4% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -48.8% vs 2.2% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -37.1% vs 1.1% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -44.5% vs 3.8% 200 mg · wk 25.71 · n 101 · Phase 2 · secondary NCT04666298
  • -46.7% vs 3.9% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -48.2% vs 2.0% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -47.0% vs 3.0% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -42.0% vs 2.8% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -44.5% vs 1.4% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -44.0% vs 2.2% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -32.5% vs 1.1% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -38.6% vs 3.8% 100 mg · wk 25.71 · n 55 · Phase 2 · secondary NCT04666298
  • -42.8% vs 3.9% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -43.4% vs 2.0% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -40.9% vs 3.0% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -35.8% vs 2.8% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -39.9% vs 1.4% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -39.7% vs 2.2% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -28.2% vs 1.1% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298
-37.0% vs 2.9%−39.9 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -36.9% vs 2.4% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -34.3% vs 2.9% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -33.9% vs 2.4% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -25.4% vs 2.9% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -24.5% vs 2.4% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -24.1% vs 2.9% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
  • -23.4% vs 2.4% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
Lp(a), % change-9.3% vs 3.6%−12.9 vs placebowk 51.43 · n 92NCT04652726
34 other results
  • -5.0% vs 1.1% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -7.2% vs 1.1% wk 47.14 · n 92 · Phase 3 · secondary NCT04652726
  • -4.8% vs 4.9% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -13.4% vs 5.4% wk 21.43 · n 92 · Phase 3 · secondary NCT04652726
  • -23.8% vs 6.4% wk 21.43 · n 103 · Phase 3 · secondary NCT05888103
  • -3.8% vs 15.2% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -4.6% vs 4.3% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -1.7% vs -12.1% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -0.3% vs -16.5% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -0.7% vs -4.4% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -35.4% vs 5.5% 300 mg · wk 25.71 · n 98 · Phase 2 · secondary NCT04666298
  • -38.1% vs 4.0% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -37.2% vs 0.2% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -37.9% vs -2.4% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -34.3% vs 4.3% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -36.2% vs -4.3% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -31.3% vs 0.9% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -22.8% vs 3.3% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -25.5% vs 5.5% 200 mg · wk 25.71 · n 101 · Phase 2 · secondary NCT04666298
  • -21.6% vs 4.0% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -30.3% vs 0.2% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -26.0% vs -2.4% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -24.9% vs 4.3% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -26.1% vs -4.3% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -22.8% vs 0.9% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -16.6% vs 3.3% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -30.1% vs 5.5% 100 mg · wk 25.71 · n 55 · Phase 2 · secondary NCT04666298
  • -32.2% vs 4.0% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -31.5% vs 0.2% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -32.0% vs -2.4% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -27.1% vs 4.3% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -30.9% vs -4.3% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -28.1% vs 0.9% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -21.8% vs 3.3% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298
-19.4% vs 0%−19.4 vs placebo30 mg · wk 12 · n 76NCT06173570
3 other results
  • -19.6% vs 0% 10 mg · wk 12 · n 81 · Phase 2 · secondary NCT06173570
  • -11.2% vs 0% 3 mg · wk 12 · n 75 · Phase 2 · secondary NCT06173570
  • -7.5% vs 0% 1 mg · wk 12 · n 75 · Phase 2 · secondary NCT06173570
3-point MACE (% with event)—Not posted · NCT05004675—Trial running · NCT06834932

LDL-C, % change

Inclisiran
-49.3% vs 4.2%−53.5 vs placebowk 72.9 · n 810NCT03400800
76 other results
  • -56.3% vs 1.3% wk 72.9 · n 781 · Phase 3 · primary NCT03399370
  • -45.8% vs 3.4% n 810 · Phase 3 · primary NCT03400800
  • -51.3% vs 2.5% n 781 · Phase 3 · primary NCT03399370
  • -41.1% vs 8.4% wk 73 · n 242 · Phase 3 · primary NCT03397121
  • -27.1% vs 1.4% wk 47.14 · n 93 · Phase 3 · primary NCT04652726
  • -45.9% vs 1.6% wk 21.43 · n 103 · Phase 3 · primary NCT05888103
  • -38.1% vs 6.2% n 242 · Phase 3 · primary NCT03397121
  • 0.7% vs 2.4% wk 21.43 · n 37 · Phase 3 · primary NCT03851705
  • -21.6% vs 11.7% wk 47.14 · n 9 · Phase 3 · primary NCT04659863
  • -45.6% vs 1.4% wk 47 · n 171 · Phase 3 · primary NCT04873934
  • -60% vs -7% wk 47 · n 205 · Phase 3 · primary NCT04929249
  • -26.1% vs 1.5% wk 51.43 · n 93 · Phase 3 · secondary NCT04652726
  • -26.0% vs 3.3% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -27.8% vs 1.5% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -19% vs 2.1% wk 38.57 · n 93 · Phase 3 · secondary NCT04652726
  • -7.2% vs -1.5% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -32.5% vs 6.4% wk 21.43 · n 93 · Phase 3 · secondary NCT04652726
  • 1.8% vs -2.9% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -23.9% vs -0.1% wk 12.86 · n 93 · Phase 3 · secondary NCT04652726
  • -8.7% vs 3.3% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -19.3% vs 5.4% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -21.6% vs 11.7% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -17.3% vs 10.2% wk 38.57 · n 9 · Phase 3 · secondary NCT04659863
  • -24.1% vs 17% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -26.1% vs 6.8% wk 12.86 · n 9 · Phase 3 · secondary NCT04659863
  • -44.3% vs 2.4% n 194 · Phase 3 · secondary NCT04873934
  • -57.2% vs -2.8% n 222 · Phase 3 · secondary NCT04929249
  • -56.3% vs 9% 300 mg · wk 25.714 · n 96 · Phase 2 · primary NCT04666298
  • -38.4% vs 2.1% 300 mg single dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -52.6% vs 2.1% 300 mg double dose · wk 25.71 · n 59 · Phase 2 · primary NCT02597127
  • -41.9% vs 2.1% 500 mg single dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -51.9% vs 9% 200 mg · wk 25.714 · n 101 · Phase 2 · primary NCT04666298
  • -27.9% vs 2.1% 200 mg single dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -44.9% vs 2.1% 200 mg double dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -47.6% vs 9% 100 mg · wk 25.714 · n 55 · Phase 2 · primary NCT04666298
  • -35.5% vs 2.1% 100 mg double dose · wk 25.71 · n 59 · Phase 2 · primary NCT02597127
  • -59.5% vs -24.3% wk 51.4 · n 898 · Phase 4 · secondary NCT05192941
  • -35.4% vs 1.4% 300 mg single dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -50.5% vs 1.4% 300 mg double dose · wk 30 · n 59 · Phase 2 · secondary NCT02597127
  • -66.2% vs 4.3% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -67.2% vs 2.3% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -43.3% vs -0.9% 300 mg single dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -54.7% vs -0.9% 300 mg double dose · wk 17.14 · n 59 · Phase 2 · secondary NCT02597127
  • -65.7% vs 1.2% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -61.5% vs 2.7% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -62.4% vs 0.2% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -50.9% vs -4.3% 300 mg single dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -51.0% vs -4.3% 300 mg double dose · wk 8.57 · n 59 · Phase 2 · secondary NCT02597127
  • -62.8% vs 1.3% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -47.6% vs 1.7% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -39.2% vs 1.4% 500 mg single dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -46.4% vs -0.9% 500 mg single dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -49.6% vs -4.3% 500 mg single dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -29.0% vs 1.4% 200 mg single dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -42.6% vs 1.4% 200 mg double dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -60.5% vs 4.3% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -62.0% vs 2.3% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -36.9% vs -0.9% 200 mg single dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -49.5% vs -0.9% 200 mg double dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -60.3% vs 1.2% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -53.9% vs 2.7% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -55.6% vs 0.2% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -44.3% vs -4.3% 200 mg single dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -44.3% vs -4.3% 200 mg double dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -55.5% vs 1.3% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -42.1% vs 1.7% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -31.7% vs 1.4% 100 mg double dose · wk 30 · n 59 · Phase 2 · secondary NCT02597127
  • -55.5% vs 4.3% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -54.9% vs 2.3% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -41.4% vs -0.9% 100 mg double dose · wk 17.14 · n 59 · Phase 2 · secondary NCT02597127
  • -53% vs 1.2% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -46.4% vs 2.7% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -50.1% vs 0.2% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -35.7% vs -4.3% 100 mg double dose · wk 8.57 · n 59 · Phase 2 · secondary NCT02597127
  • -52.2% vs 1.3% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -37.1% vs 1.7% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298
Laroprovstat
-46.6% vs 4.1%−50.7 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -41.1% vs 4.1% 10 mg · wk 12 · n 84 · Phase 2 · primary NCT06173570
  • -33.8% vs 4.1% 3 mg · wk 12 · n 85 · Phase 2 · primary NCT06173570
  • -31.2% vs 4.1% 1 mg · wk 12 · n 86 · Phase 2 · primary NCT06173570
  • -46.4% vs 3.4% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -40.5% vs 3.4% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -33.4% vs 3.4% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -30.5% vs 3.4% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570

Non-HDL-C, % change

Inclisiran
-41.2% vs 2.1%−43.3 vs placebowk 72.9 · n 810NCT03400800
38 other results
  • -47.4% vs -0.1% wk 72.9 · n 781 · Phase 3 · secondary NCT03399370
  • -34.9% vs 7.4% wk 73 · n 242 · Phase 3 · secondary NCT03397121
  • -24% vs 1.2% wk 51.43 · n 92 · Phase 3 · secondary NCT04652726
  • -25.0% vs 1.8% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -25.7% vs 1.8% wk 47.14 · n 92 · Phase 3 · secondary NCT04652726
  • -6.2% vs -1.1% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -29% vs 5.1% wk 21.43 · n 92 · Phase 3 · secondary NCT04652726
  • -40.7% vs -0.1% wk 21.43 · n 103 · Phase 3 · secondary NCT05888103
  • 1.3% vs -1.7% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • 0.4% vs 2.5% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -7.2% vs 2.9% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -20.1% vs 7.1% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -23.3% vs 9.4% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -24% vs 19% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -54.0% vs 1.3% 300 mg · wk 25.71 · n 98 · Phase 2 · secondary NCT04666298
  • -56.8% vs 2.0% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -58.7% vs 0.8% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -57.7% vs 2.0% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -53.2% vs 1.8% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -54.1% vs 0.6% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -54.2% vs 1.0% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -41.2% vs 1.1% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -50.1% vs 1.3% 200 mg · wk 25.71 · n 101 · Phase 2 · secondary NCT04666298
  • -52.9% vs 2.0% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -53.5% vs 0.8% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -52.0% vs 2.0% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -47.2% vs 1.8% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -48.2% vs 0.6% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -48.0% vs 1.0% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -35.7% vs 1.1% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -44.8% vs 1.3% 100 mg · wk 25.71 · n 55 · Phase 2 · secondary NCT04666298
  • -47.9% vs 2.0% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -48.2% vs 0.8% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -46.1% vs 2.0% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -39.8% vs 1.8% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -43.4% vs 0.6% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -44.7% vs 1.0% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -31.4% vs 1.1% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298
Laroprovstat
-41.6% vs 3.5%−45.2 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -41.4% vs 2.9% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -35.1% vs 3.5% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -34.8% vs 2.9% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -29.9% vs 3.5% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -29.4% vs 2.9% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -26.9% vs 3.5% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
  • -26.1% vs 2.9% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570

ApoB, % change

Inclisiran
-38.1% vs 0.8%−38.9 vs placebowk 72.9 · n 810NCT03400800
38 other results
  • -44.8% vs -1.7% wk 72.9 · n 781 · Phase 3 · secondary NCT03399370
  • -33.1% vs 2.9% wk 73 · n 242 · Phase 3 · secondary NCT03397121
  • -19.3% vs 1.7% wk 51.43 · n 92 · Phase 3 · secondary NCT04652726
  • -21.5% vs 4.2% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -21.9% vs 3.9% wk 47.14 · n 92 · Phase 3 · secondary NCT04652726
  • -5.8% vs 4.5% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -25.1% vs 2.2% wk 21.43 · n 92 · Phase 3 · secondary NCT04652726
  • -36.6% vs 0.2% wk 21.43 · n 103 · Phase 3 · secondary NCT05888103
  • -0.7% vs 2.8% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -0.8% vs 3.5% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -6.4% vs 6.3% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -14.8% vs 10.6% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -18.5% vs 4.5% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -20.3% vs 10% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -46.8% vs 3.8% 300 mg · wk 25.71 · n 98 · Phase 2 · secondary NCT04666298
  • -50.4% vs 3.9% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -51.9% vs 2.0% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -51.9% vs 3.0% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -46.8% vs 2.8% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -48.5% vs 1.4% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -48.8% vs 2.2% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -37.1% vs 1.1% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -44.5% vs 3.8% 200 mg · wk 25.71 · n 101 · Phase 2 · secondary NCT04666298
  • -46.7% vs 3.9% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -48.2% vs 2.0% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -47.0% vs 3.0% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -42.0% vs 2.8% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -44.5% vs 1.4% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -44.0% vs 2.2% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -32.5% vs 1.1% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -38.6% vs 3.8% 100 mg · wk 25.71 · n 55 · Phase 2 · secondary NCT04666298
  • -42.8% vs 3.9% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -43.4% vs 2.0% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -40.9% vs 3.0% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -35.8% vs 2.8% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -39.9% vs 1.4% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -39.7% vs 2.2% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -28.2% vs 1.1% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298
Laroprovstat
-37.0% vs 2.9%−39.9 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -36.9% vs 2.4% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -34.3% vs 2.9% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -33.9% vs 2.4% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -25.4% vs 2.9% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -24.5% vs 2.4% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -24.1% vs 2.9% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
  • -23.4% vs 2.4% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570

Lp(a), % change

Inclisiran
-9.3% vs 3.6%−12.9 vs placebowk 51.43 · n 92NCT04652726
34 other results
  • -5.0% vs 1.1% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -7.2% vs 1.1% wk 47.14 · n 92 · Phase 3 · secondary NCT04652726
  • -4.8% vs 4.9% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -13.4% vs 5.4% wk 21.43 · n 92 · Phase 3 · secondary NCT04652726
  • -23.8% vs 6.4% wk 21.43 · n 103 · Phase 3 · secondary NCT05888103
  • -3.8% vs 15.2% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -4.6% vs 4.3% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -1.7% vs -12.1% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -0.3% vs -16.5% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -0.7% vs -4.4% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -35.4% vs 5.5% 300 mg · wk 25.71 · n 98 · Phase 2 · secondary NCT04666298
  • -38.1% vs 4.0% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -37.2% vs 0.2% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -37.9% vs -2.4% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -34.3% vs 4.3% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -36.2% vs -4.3% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -31.3% vs 0.9% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -22.8% vs 3.3% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -25.5% vs 5.5% 200 mg · wk 25.71 · n 101 · Phase 2 · secondary NCT04666298
  • -21.6% vs 4.0% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -30.3% vs 0.2% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -26.0% vs -2.4% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -24.9% vs 4.3% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -26.1% vs -4.3% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -22.8% vs 0.9% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -16.6% vs 3.3% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -30.1% vs 5.5% 100 mg · wk 25.71 · n 55 · Phase 2 · secondary NCT04666298
  • -32.2% vs 4.0% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -31.5% vs 0.2% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -32.0% vs -2.4% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -27.1% vs 4.3% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -30.9% vs -4.3% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -28.1% vs 0.9% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -21.8% vs 3.3% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298
Laroprovstat
-19.4% vs 0%−19.4 vs placebo30 mg · wk 12 · n 76NCT06173570
3 other results
  • -19.6% vs 0% 10 mg · wk 12 · n 81 · Phase 2 · secondary NCT06173570
  • -11.2% vs 0% 3 mg · wk 12 · n 75 · Phase 2 · secondary NCT06173570
  • -7.5% vs 0% 1 mg · wk 12 · n 75 · Phase 2 · secondary NCT06173570

3-point MACE (% with event)

Inclisiran
—Not posted · NCT05004675
Laroprovstat
—Trial running · NCT06834932
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety

Coverage. Inclisiran: 9 of 9 rows · Laroprovstat: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricInclisiran
Rows use multiple source trials
Laroprovstat
Apo A1
percent change · % of baseline
3% (n=92) vs -1.5% (n=48) placebo @ 51.43wka,b,c,d
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
5.72% (n=85) vs 4.46% (n=86) placebo @ 12wk30 mge,a,b,c,d
NCT06173570 · Phase 2
show 7 more doses
5.55% (n=85) vs 3.82% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
3.61% (n=84) vs 4.46% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
3.79% (n=84) vs 3.82% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
3.25% (n=85) vs 4.46% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
2.89% (n=85) vs 3.82% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
1.67% (n=86) vs 4.46% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
2.52% (n=86) vs 3.82% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
HDL-C
percent change · % of baseline
4.4% (n=92) vs 0.9% (n=48) placebo @ 51.43wka,b,c,d
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
4.66% (n=85) vs 3.65% (n=86) placebo @ 12wk30 mge,a,b,c,d
NCT06173570 · Phase 2
show 7 more doses
4.65% (n=85) vs 3.11% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
1.97% (n=84) vs 3.65% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
2.17% (n=84) vs 3.11% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
4.03% (n=85) vs 3.65% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
3.66% (n=85) vs 3.11% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
0.12% (n=86) vs 3.65% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
0.8% (n=86) vs 3.11% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
Total Cholesterol
percent change · % of baseline
-28% (n=810) vs 1.79% (n=807) placebo @ 72.9wka,b,c,f
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
1 other source trial
-33.56% (n=781) vs -0.42% (n=781) placebo @ 72.9wk
NCT03399370 · Phase 3
-27.06% (n=85) vs 2.29% (n=86) placebo @ 12wk30 mge,a,b,c,f
NCT06173570 · Phase 2
show 7 more doses
-26.9% (n=85) vs 1.73% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
-24.84% (n=84) vs 2.29% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-24.54% (n=84) vs 1.73% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-20.09% (n=85) vs 2.29% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-19.8% (n=85) vs 1.73% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-18.93% (n=86) vs 2.29% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
-18.23% (n=86) vs 1.73% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
Triglycerides
percent change · % of baseline
1.7% (n=92) vs 3.8% (n=48) placebo @ 51.43wka,b,c,d
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-0.44% (n=85) vs 9.56% (n=86) placebo @ 12wk30 mge,a,b,c,d
NCT06173570 · Phase 2
show 7 more doses
-0.83% (n=85) vs 9.04% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
1.93% (n=84) vs 9.56% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
1.72% (n=84) vs 9.04% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
2.9% (n=85) vs 9.56% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
2.17% (n=85) vs 9.04% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
3.06% (n=86) vs 9.56% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
2.81% (n=86) vs 9.04% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
VLDL-C
percent change · % of baseline
1% (n=92) vs 4.7% (n=48) placebo @ 51.43wka,b,c,d
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
0.46% (n=85) vs 7.19% (n=86) placebo @ 12wk30 mge,a,b,c,d
NCT06173570 · Phase 2
show 7 more doses
0.42% (n=85) vs 6.74% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
2.21% (n=84) vs 7.19% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
1.77% (n=84) vs 6.74% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
4.02% (n=85) vs 7.19% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
2.67% (n=85) vs 6.74% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
1.13% (n=86) vs 7.19% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
0.81% (n=86) vs 6.74% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
Dropout rate
2.9%g
NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 46 more results
—Part 1 - Inclisiran
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
2.2%Part 1- Inclisiran
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—Part 1 - Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
0%Part 1- Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 2 - Inclisiran (Total)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
4.7%
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
7.7%
NCT03399370 · Phase 3
2%
NCT05192941 · Phase 4 · registry result, not featured evidence
2.9%Inclisiran - Inclisiran
NCT05888103 · Phase 3 · registry result, not featured evidence
—Inclisiran - Inclisiran: Core Part
NCT05888103 · Phase 3 · registry result, not featured evidence
—Inclisiran - Inclisiran: Extension
NCT05888103 · Phase 3 · registry result, not featured evidence
—Inclisiran + Usual Care
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
9%Inclisiran With Usual Care
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
5.7%
NCT05763875 · Phase 3 · registry result, not featured evidence
5.8%
NCT04929249 · Phase 3 · registry result, not featured evidence
100%ORION-3 Rollover
NCT03814187 · Phase 3 · registry result, not featured evidence
17.6%Phase III Inclisiran-Inclisiran
NCT03814187 · Phase 3 · registry result, not featured evidence
18.8%Phase III Placebo-Inclisiran
NCT03814187 · Phase 3 · registry result, not featured evidence
16.8%Inclisiran
NCT04807400 · Phase 3 · registry result, not featured evidence
15.2%Inclisiran + BS
NCT04807400 · Phase 3 · registry result, not featured evidence · combination
8.1%Part 1 - Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 1: Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 2 - Inclisiran-Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 2: Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
4%300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
1%200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
0%100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—Inclisiran Only Arm
NCT03060577 · Phase 2 · registry result, not featured evidence
19.7%Inclisiran-only
NCT03060577 · Phase 2 · registry result, not featured evidence
—Switching Arm After Day 360 Visit
NCT03060577 · Phase 2 · registry result, not featured evidence
55.6%
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
—300 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
6.6%300 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—300 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
4.8%300 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—500 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
12.1%500 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
6.3%200 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
1.7%200 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—100 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
8.1%100 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
5.9%30 mgh
NCT06173570 · Phase 2
show 3 more results
1.2%10 mg
NCT06173570 · Phase 2
4.7%3 mg
NCT06173570 · Phase 2
5.8%1 mg
NCT06173570 · Phase 2
Discontinued due to AEs
—g
NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 46 more results
—Part 1 - Inclisiran
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—Part 1- Inclisiran
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—Part 1 - Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 1- Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 2 - Inclisiran (Total)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—
NCT03399370 · Phase 3
0.3%
NCT05192941 · Phase 4 · registry result, not featured evidence
—Inclisiran - Inclisiran
NCT05888103 · Phase 3 · registry result, not featured evidence
—Inclisiran - Inclisiran: Core Part
NCT05888103 · Phase 3 · registry result, not featured evidence
—Inclisiran - Inclisiran: Extension
NCT05888103 · Phase 3 · registry result, not featured evidence
—Inclisiran + Usual Care
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
0%Inclisiran With Usual Care
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
0.6%
NCT05763875 · Phase 3 · registry result, not featured evidence
0.9%
NCT04929249 · Phase 3 · registry result, not featured evidence
0%ORION-3 Rollover
NCT03814187 · Phase 3 · registry result, not featured evidence
1.5%Phase III Inclisiran-Inclisiran
NCT03814187 · Phase 3 · registry result, not featured evidence
1.6%Phase III Placebo-Inclisiran
NCT03814187 · Phase 3 · registry result, not featured evidence
0.7%Inclisiran
NCT04807400 · Phase 3 · registry result, not featured evidence
1%Inclisiran + BS
NCT04807400 · Phase 3 · registry result, not featured evidence · combination
—Part 1 - Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 1: Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 2 - Inclisiran-Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 2: Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—Inclisiran Only Arm
NCT03060577 · Phase 2 · registry result, not featured evidence
3.1%Inclisiran-only
NCT03060577 · Phase 2 · registry result, not featured evidence
—Switching Arm After Day 360 Visit
NCT03060577 · Phase 2 · registry result, not featured evidence
—
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
—300 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—300 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—300 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—300 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—500 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—500 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—100 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—100 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
2.4%30 mgh
NCT06173570 · Phase 2
show 3 more results
0%10 mg
NCT06173570 · Phase 2
0%3 mg
NCT06173570 · Phase 2
1.2%1 mg
NCT06173570 · Phase 2
Serious AEs
7.5%g
NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 46 more results
3.2%Part 1 - Inclisiran
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—Part 1- Inclisiran
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
0%Part 1 - Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 1- Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
0%Part 2 - Inclisiran (Total)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
22.3%
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
22.4%
NCT03399370 · Phase 3
16.4%
NCT05192941 · Phase 4 · registry result, not featured evidence
—Inclisiran - Inclisiran
NCT05888103 · Phase 3 · registry result, not featured evidence
4.9%Inclisiran - Inclisiran: Core Part
NCT05888103 · Phase 3 · registry result, not featured evidence
1%Inclisiran - Inclisiran: Extension
NCT05888103 · Phase 3 · registry result, not featured evidence
15.8%Inclisiran + Usual Care
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
—Inclisiran With Usual Care
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
0.6%
NCT05763875 · Phase 3 · registry result, not featured evidence
11.5%
NCT04929249 · Phase 3 · registry result, not featured evidence
15.1%ORION-3 Rollover
NCT03814187 · Phase 3 · registry result, not featured evidence
30.7%Phase III Inclisiran-Inclisiran
NCT03814187 · Phase 3 · registry result, not featured evidence
32.6%Phase III Placebo-Inclisiran
NCT03814187 · Phase 3 · registry result, not featured evidence
8.8%Inclisiran
NCT04807400 · Phase 3 · registry result, not featured evidence
12.8%Inclisiran + BS
NCT04807400 · Phase 3 · registry result, not featured evidence · combination
—Part 1 - Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
5.4%Part 1: Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 2 - Inclisiran-Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
20.8%Part 2: Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
7.1%300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
6.9%200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
3.6%100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
36.6%Inclisiran Only Arm
NCT03060577 · Phase 2 · registry result, not featured evidence
—Inclisiran-only
NCT03060577 · Phase 2 · registry result, not featured evidence
34.5%Switching Arm After Day 360 Visit
NCT03060577 · Phase 2 · registry result, not featured evidence
25%
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
14.8%300 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—300 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
18%300 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—300 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
12.3%500 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—500 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
12.9%200 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
18.3%200 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
21.3%100 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—100 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
1.2%30 mgh
NCT06173570 · Phase 2
show 3 more results
2.4%10 mg
NCT06173570 · Phase 2
2.4%3 mg
NCT06173570 · Phase 2
2.3%1 mg
NCT06173570 · Phase 2
Most frequent reported AEs
g
nasopharyngitis 11.6% (placebo 8.3%)
injection site reaction 9.1% (placebo 0%)
back pain 7.1% (placebo 4.2%)
NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 30 more results
covid-19 18.3% (placebo 25%)
nasopharyngitis 14% (placebo 18.8%)
headache 12.9% (placebo 6.3%)
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
covid-19 44.4% (placebo 25%)
abdominal pain upper 22.2% (placebo 0%)
injection site reaction 22.2% (placebo 0%)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
headache 15.4% (placebo 0%)
influenza 15.4% (placebo 0%)
abdominal pain upper 7.7% (placebo 0%)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
nasopharyngitis 11.2% (placebo 11.2%)
diabetes mellitus 10.9% (placebo 11.7%)
hypertension 6.5% (placebo 6.7%)
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
diabetes mellitus 15.4% (placebo 13.9%)
bronchitis 5.9% (placebo 3.9%)
hypertension 5.4% (placebo 5.4%)
NCT03399370 · Phase 3
nasopharyngitis 8.2% (placebo 9.1%)
covid-19 6.1% (placebo 6.3%)
diabetes mellitus inadequate control 6.1% (placebo 5.6%)
NCT05192941 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 24.3% (placebo 16.3%)
blood glucose increased 9.7% (placebo 6.7%)
blood creatine phosphokinase increased 6.8% (placebo 5.8%)
NCT05888103 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 14% (placebo 16.3%)
blood creatine phosphokinase increased 6% (placebo 5.8%)
alanine aminotransferase increased 5% (placebo 2.9%)
NCT05888103 · Phase 3 · registry result, not featured evidence
covid-19 4.9%
injection site pain 4.9%
arthralgia 3.9%
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
headache 3.4% (placebo 0%)
nasopharyngitis 3.4% (placebo 3.4%)
urinary tract infection 1.7% (placebo 2.3%)
NCT05763875 · Phase 3 · registry result, not featured evidence
covid-19 7.7%
injection site pain 7.7%
blood creatine phosphokinase increased 4.3%
NCT04929249 · Phase 3 · registry result, not featured evidence
covid-19 18.3%
urinary tract infection 3.5%
hypertension 3.2%
NCT03814187 · Phase 3 · registry result, not featured evidence
covid-19 11.8%
diabetes mellitus inadequate control 7.5%
hypertension 7%
NCT03814187 · Phase 3 · registry result, not featured evidence
covid-19 11.9%
diabetes mellitus inadequate control 7.4%
hypertension 7.4%
NCT03814187 · Phase 3 · registry result, not featured evidence
back pain 0.4%
injection site rash 0.4%
muscle spasms 0.4%
NCT04807400 · Phase 3 · registry result, not featured evidence
dizziness 0.4%
rash 0.4%
back pain 0%
NCT04807400 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 5.4% (placebo 0%)
pyrexia 5.4% (placebo 0%)
respiratory tract infection viral 5.4% (placebo 10.5%)
NCT03851705 · Phase 3 · registry result, not featured evidence
corona virus infection 7.5% (placebo 0%)
international normalised ratio increased 5.7% (placebo 0%)
activated partial thromboplastin time prolonged 3.8% (placebo 0%)
NCT03851705 · Phase 3 · registry result, not featured evidence
300 mg
pyrexia 18.2% (placebo 12.3%)
diabetes mellitus inadequate control 15.2% (placebo 15.8%)
diabetes mellitus 12.1% (placebo 8.8%)
NCT04666298 · Phase 2 · registry result, not featured evidence
200 mg
diabetes mellitus 11.9% (placebo 8.8%)
injection site reaction 11.9% (placebo 3.5%)
pyrexia 11.9% (placebo 12.3%)
NCT04666298 · Phase 2 · registry result, not featured evidence
100 mg
diabetes mellitus 20% (placebo 8.8%)
covid-19 14.5% (placebo 3.5%)
pyrexia 14.5% (placebo 12.3%)
NCT04666298 · Phase 2 · registry result, not featured evidence
nasopharyngitis 19.4% (placebo 6.7%)
hypertension 14.8% (placebo 2.2%)
arthralgia 14.1% (placebo 11.1%)
NCT03060577 · Phase 2 · registry result, not featured evidence
hypertension 19.5% (placebo 2.2%)
back pain 14.9% (placebo 1.1%)
nasopharyngitis 14.9% (placebo 6.7%)
NCT03060577 · Phase 2 · registry result, not featured evidence
abdominal pain upper 25%
acne 25%
angina unstable 25%
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
300 mg double dose
nasopharyngitis 18% (placebo 12.9%)
musculoskeletal pain 9.8% (placebo 6.5%)
diarrhoea 8.2% (placebo 3.2%)
NCT02597127 · Phase 2 · registry result, not featured evidence
300 mg single dose
nasopharyngitis 14.8% (placebo 12.9%)
cough 11.5% (placebo 4.8%)
myalgia 9.8% (placebo 4.8%)
NCT02597127 · Phase 2 · registry result, not featured evidence
500 mg single dose
nasopharyngitis 13.8% (placebo 12.9%)
influenza 7.7% (placebo 3.2%)
upper respiratory tract infection 7.7% (placebo 3.2%)
NCT02597127 · Phase 2 · registry result, not featured evidence
200 mg double dose
diarrhoea 11.3% (placebo 3.2%)
cough 9.7% (placebo 4.8%)
arthralgia 8.1% (placebo 1.6%)
NCT02597127 · Phase 2 · registry result, not featured evidence
200 mg single dose
nasopharyngitis 13.3% (placebo 12.9%)
arthralgia 6.7% (placebo 1.6%)
back pain 6.7% (placebo 3.2%)
NCT02597127 · Phase 2 · registry result, not featured evidence
100 mg double dose
nasopharyngitis 13.1% (placebo 12.9%)
myalgia 11.5% (placebo 4.8%)
back pain 9.8% (placebo 3.2%)
NCT02597127 · Phase 2 · registry result, not featured evidence
30 mgh
hypertension 3.5% (placebo 5.8%)
NCT06173570 · Phase 2
show 3 more results
10 mg
hypertension 2.4% (placebo 5.8%)
NCT06173570 · Phase 2
3 mg
hypertension 2.4% (placebo 5.8%)
NCT06173570 · Phase 2
1 mg
hypertension 4.7% (placebo 5.8%)
NCT06173570 · Phase 2

Notes

  1. aTrial phases differ: Phase 3 versus Phase 2.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 51.43 weeks versus 12 weeks.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fAssessment timepoints differ: 72.9 weeks versus 12 weeks.
  7. gPopulation comparability has not been reviewed for 40 of these studies.
  8. hPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Inclisiran

LDL-C -57.7 vs 13.2 placebo mg/dL @ 25.714wk300 mg
absolute change · mg/dL
NCT04666298 · Phase 2 · registry result, not featured evidence
show 23 more results
-53.9 vs 13.2 placebo mg/dL @ 25.714wk200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-49.3 vs 13.2 placebo mg/dL @ 25.714wk100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
-50.54 vs -0.55 placebo mg/dL @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-45.4 vs -3 placebo mg/dL @ 12.86wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-61 vs 6.6 placebo mg/dL @ 21.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-38.4 vs 1 placebo mg/dL @ 38.57wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-51.9 vs -0.3 placebo mg/dL @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-49 vs -2.9 placebo mg/dL @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-50.91 vs 0.96 placebo mg/dL @ 72.9wk
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-48.63 vs 0.31 placebo mg/dL
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-56.18 vs -2.06 placebo mg/dL @ 72.9wk
NCT03399370 · Phase 3
-53.66 vs -0.39 placebo mg/dL
NCT03399370 · Phase 3
-69.05 vs 0.68 placebo mg/dL @ 21.43wk
NCT05888103 · Phase 3 · registry result, not featured evidence
-44.2 vs -2.2 Usual Care mg/dL @ 12.86wk
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
-34.6 vs -3.8 Usual Care mg/dL @ 38.57wk
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
-41.2 vs -3.5 Usual Care mg/dL @ 47.14wk
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
-40 vs -2.7 Usual Care mg/dL
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
-58 vs -10.5 Usual Care mg/dL @ 47wk
NCT04929249 · Phase 3 · registry result, not featured evidence
-55 vs -6 Usual Care mg/dL
NCT04929249 · Phase 3 · registry result, not featured evidence
-2.35 vs -8.82 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-16.3 vs 3.6 placebo mg/dL @ 12.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
0.5 vs -17.2 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-14.5 vs -7 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3 · registry result, not featured evidence
Apo B Change mg/dL -33.3 vs 0 placebo mg/dL @ 21.43wk
absolute change · mg/dL
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 6 more results
-29.2 vs 2.9 placebo mg/dL @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-26.1 vs -0.6 placebo mg/dL @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-42.64 vs -0.76 placebo mg/dL @ 21.43wk
NCT05888103 · Phase 3 · registry result, not featured evidence
-9.4 vs 10 placebo mg/dL @ 12.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-1.4 vs 3.3 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-7.4 vs 8.4 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3 · registry result, not featured evidence
Lp a Change -12.5 vs 3.2 placebo nmol/L @ 21.43wk
absolute change · nmol/L
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 6 more results
-9.5 vs 5.3 placebo nmol/L @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-10.2 vs 4.4 placebo nmol/L @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-19.3 vs -5.3 Usual Care nmol/L @ 47wk
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
-3.8 vs 5.8 placebo nmol/L @ 12.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-5.6 vs 3.9 placebo nmol/L @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-5.1 vs 1.2 placebo nmol/L @ 25.71wk
NCT03851705 · Phase 3 · registry result, not featured evidence
Non-HDL-C Change mg/dL -60.2 vs 5.7 placebo mg/dL @ 21.43wk
absolute change · mg/dL
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 6 more results
-52.6 vs 0.5 placebo mg/dL @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-49.7 vs -3 placebo mg/dL @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-73.48 vs -1.14 placebo mg/dL @ 21.43wk
NCT05888103 · Phase 3 · registry result, not featured evidence
-15.3 vs 3.8 placebo mg/dL @ 12.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
0.6 vs -11.6 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-12.7 vs -5.7 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3 · registry result, not featured evidence
Total Cholesterol Change mg/dL -59 vs 6.6 placebo mg/dL @ 21.43wk
absolute change · mg/dL
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 6 more results
-49.4 vs -0.9 placebo mg/dL @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-48.2 vs -3.1 placebo mg/dL @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-68.82 vs 2.64 placebo mg/dL @ 21.43wk
NCT05888103 · Phase 3 · registry result, not featured evidence
-15.1 vs 3.9 placebo mg/dL @ 12.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
0.6 vs -10.5 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-12.6 vs -6.8 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3 · registry result, not featured evidence
Triglycerides 6.9 vs -4.8 placebo mg/dL @ 21.43wk
absolute change · mg/dL
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 2 more results
-2.9 vs 3.5 placebo mg/dL @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-3.1 vs -1.7 placebo mg/dL @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
HDL-C Change mg/dL 1.2 vs 0.9 placebo mg/dL @ 21.43wk
absolute change · mg/dL
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 6 more results
3.2 vs -1.4 placebo mg/dL @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
1.5 vs -0.1 placebo mg/dL @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
4.66 vs 3.6 placebo mg/dL @ 21.43wk
NCT05888103 · Phase 3 · registry result, not featured evidence
0.2 vs 0 placebo mg/dL @ 12.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
0 vs 1 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
0 vs -1.2 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3 · registry result, not featured evidence
VLDL-C Change mg/dL 0.7 vs -0.9 placebo mg/dL @ 21.43wk
absolute change · mg/dL
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 5 more results
-0.7 vs 0.8 placebo mg/dL @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-0.7 vs -0.2 placebo mg/dL @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
1.6 vs 0.6 placebo mg/dL @ 12.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
0.4 vs 3 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
1.5 vs 1.8 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3 · registry result, not featured evidence
Apo-A1 Change mg/dL 3.3 vs 0 placebo mg/dL @ 21.43wk
absolute change · mg/dL
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 6 more results
6.1 vs -2.8 placebo mg/dL @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
2.7 vs -2.6 placebo mg/dL @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
6.44 vs 3.31 placebo mg/dL @ 21.43wk
NCT05888103 · Phase 3 · registry result, not featured evidence
0.6 vs 2.6 placebo mg/dL @ 12.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-1.4 vs 4 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-1.3 vs 1.4 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3 · registry result, not featured evidence
LDL-C -49% (n=60) @ 12.86wk500 mg single dose
percent change · % of baseline
No placebo or comparator arm
NCT02597127 · Phase 2 · registry result, not featured evidence
show 22 more results
-34.2% (n=59) @ 12.86wk100 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
-11% (n=13) @ 64.29wk
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
-12.5% (n=13) @ 72.86wk
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
-9.4% (n=13) @ 90wk
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
-12.6% (n=13) @ 102.86wk
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
-37.3% (n=294) @ 38.571wk
NCT04807400 · Phase 3 · registry result, not featured evidence
-37.6% (n=295) @ 38.571wk
NCT04807400 · Phase 3 · registry result, not featured evidence · combination
-9.1% (n=34) @ 38.57wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-4.8% (n=34) @ 47.14wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-4.7% (n=34) @ 64.29wk
NCT03851705 · Phase 3 · registry result, not featured evidence
2.4% (n=34) @ 72.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-6.6% (n=34) @ 90wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-4.2% (n=34) @ 98.57wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-6.2% (n=34) @ 102.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-47.48% (n=277) @ 81.4wk
NCT03060577 · Phase 2 · registry result, not featured evidence
-49.43% (n=277) @ 4.29wk
NCT03060577 · Phase 2 · registry result, not featured evidence
-37.14% (n=277) @ 51.43wk
NCT03060577 · Phase 2 · registry result, not featured evidence
-38.43% (n=277) @ 102.86wk
NCT03060577 · Phase 2 · registry result, not featured evidence
-51.07% (n=277) @ 154.29wk
NCT03060577 · Phase 2 · registry result, not featured evidence
-46.74% (n=277) @ 205.71wk
NCT03060577 · Phase 2 · registry result, not featured evidence
-12.26% (n=4) @ 13wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
-20.96% (n=4) @ 26wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
Apo B -5.7% (n=13) @ 72.86wk
percent change · % of baseline
No placebo or comparator arm
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
show 13 more results
-7.3% (n=13) @ 102.86wk
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
-3.3% (n=34) @ 38.57wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-3.6% (n=34) @ 47.14wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-3.5% (n=34) @ 64.29wk
NCT03851705 · Phase 3 · registry result, not featured evidence
1.9% (n=34) @ 72.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-6.6% (n=34) @ 90wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-5.8% (n=34) @ 98.57wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-8% (n=34) @ 102.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-40.43% (n=277) @ 4.29wk
NCT03060577 · Phase 2 · registry result, not featured evidence
-36.65% (n=277) @ 30wk
NCT03060577 · Phase 2 · registry result, not featured evidence
-33.66% (n=277) @ 205.71wk
NCT03060577 · Phase 2 · registry result, not featured evidence
-26.6% (n=4) @ 12.86wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
-25% (n=4) @ 25.71wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
Lp(a -7.2% (n=13) @ 72.86wk
percent change · % of baseline
No placebo or comparator arm
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
show 12 more results
-8.8% (n=13) @ 102.86wk
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
-1.4% (n=34) @ 47.14wk
NCT03851705 · Phase 3 · registry result, not featured evidence
0.2% (n=34) @ 64.29wk
NCT03851705 · Phase 3 · registry result, not featured evidence
13.4% (n=34) @ 72.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
1.7% (n=34) @ 90wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-5.3% (n=34) @ 98.57wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-3.1% (n=34) @ 102.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-15.88% (n=277) @ 4.29wk
NCT03060577 · Phase 2 · registry result, not featured evidence
9.29% (n=277) @ 30wk
NCT03060577 · Phase 2 · registry result, not featured evidence
-5.24% (n=277) @ 205.71wk
NCT03060577 · Phase 2 · registry result, not featured evidence
-3.5% (n=4) @ 12.86wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
-11.8% (n=4) @ 25.71wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy

+ 49 further endpoints in the CSV export.

Laroprovstat

Remnant Cholesterol -18.31% (n=77) vs -5% (n=80) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 3 more results
-22.95% (n=79) vs -5% (n=80) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-8.33% (n=75) vs -5% (n=80) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-9.09% (n=75) vs -5% (n=80) placebo @ 12wk1 mg
NCT06173570 · Phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Inclisiran's landscape · Laroprovstat's landscape